Duvelisib: all 50 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesNot yet recruitingNCT07714187Phase 1
• Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasRecruitingNCT07293403Phase 2
• A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingNCT07001384Phase 1
• Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT06810778Phase 1/2
• A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingNCT06522737Phase 3
• Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05976997Phase 2
• A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsNot yet recruitingNCT05508659Phase 1/2
• A Study of Ruxolitinib and Duvelisib in People With LymphomaRecruitingNCT05010005Phase 1
• Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingNCT04803201Phase 2
• Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCCCompletedNCT05057247Phase 2Results posted
• Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable MelanomaTerminatedNCT04688658Phase 1/2Results posted
• Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)CompletedNCT04487886Phase 2Results posted
• Duvelisib to Combat COVID-19CompletedNCT04372602Phase 2Results posted
• Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04209621Phase 2Results posted
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerTerminatedNCT04193293Phase 1/2Results posted
• A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaCompletedNCT04038359Phase 2Results posted
• Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT03961672Phase 2Results posted
• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSActive, not recruitingNCT03534323Phase 1/2Results posted
• A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT03372057Phase 2Results posted
• A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)CompletedNCT02711852Phase 2Results posted
• Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaTerminatedNCT02204982Phase 3Results posted
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingNCT02158091Phase 1/2Results posted
• A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07CompletedNCT02049515Phase 3Results posted
• A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)CompletedNCT02004522Phase 3Results posted
• A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaCompletedNCT01882803Phase 2Results posted
• Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedNCT05065866Phase 1
• Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyActive, not recruitingNCT05044039Phase 1
• Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyCompletedNCT04890236Early Phase 1
• Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT04836832Phase 1
• A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular LymphomaStatus unknownNCT04707079Phase 2
• Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeActive, not recruitingNCT04652960Phase 1
• Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaWithdrawnNCT04639843Phase 1
• Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell LymphomasTerminatedNCT04331119Phase 2
• Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
• Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaWithdrawnNCT03370185Phase 2
• A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
• Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)WithdrawnNCT02605694Phase 2
• Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory LymphomaCompletedNCT02598570Phase 1
• A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)WithdrawnNCT02576275Phase 3
• Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145CompletedNCT02307461Phase 1
• Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)TerminatedNCT02292225Phase 1
• Duvelisib in Hepatically Impaired Subjects Compared to Healthy SubjectsCompletedNCT02095587Phase 1
• IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT02028039Phase 2
• Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145CompletedNCT01947777Phase 1
• Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of MidazolamCompletedNCT01925911Phase 1
• A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AloneCompletedNCT01851707Phase 2
• IPI-145 ADME and Absolute Bioavailability StudyCompletedNCT01836861Phase 1
• A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic SubjectsCompletedNCT01653756Phase 2
• IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction StudyCompletedNCT01549106Phase 1
• A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic MalignanciesTerminatedNCT01476657Phase 1

← Duvelisib overview